BACKGROUND: Comparing findings from separate trials is necessary to choose among treatment options, however differences among study cohorts may impede these comparisons. PURPOSE: As a case study, to examine the overlap of study cohorts in two large randomized controlled clinical trials that assess interventions to reduce risk of major cardiovascular disease events in adults with type 2 diabetes in order to explore the feasibility of cross-trial comparisons METHODS: The Action for Health in Diabetes (Look AHEAD) and The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials enrolled 5145 and 10,251 adults with type 2 diabetes, respectively. Look AHEAD assesses the efficacy of an intensive lifestyle intervention designed to produce weight loss; ACCORD tests pharmacological therapies for control of glycemia, hyperlipidemia, and hypertension. Incidence of major cardiovascular disease events is the primary outcome for both trials. A sample was constructed to include participants from each trial who appeared to meet eligibility criteria and be appropriate candidates for the other trial's interventions. Demographic characteristics, health status, and outcomes of members and nonmembers of this constructed sample were compared. RESULTS: Nearly 80% of Look AHEAD participants were projected to be ineligible for ACCORD; ineligibility was primarily due to better glycemic control or no early history of cardiovascular disease. Approximately 30% of ACCORD participants were projected to be ineligible for Look AHEAD, often for reasons linked to poorer health. The characteristics of participants projected to be jointly eligible for both trials continued to reflect differences between trials according to factors likely linked to retention, adherence, and study outcomes. LIMITATIONS: Accurate ascertainment of cross-trial eligibility was hampered by differences between protocols. CONCLUSIONS: Despite several similarities, the Look AHEAD and ACCORD cohorts represent distinct populations. Even within the subsets of participants who appear to be eligible and appropriate candidates for trials of both modes of intervention, differences remained. Direct comparisons of results from separate trials of lifestyle and pharmacologic interventions are compromised by marked differences in enrolled cohorts.
BACKGROUND: Comparing findings from separate trials is necessary to choose among treatment options, however differences among study cohorts may impede these comparisons. PURPOSE: As a case study, to examine the overlap of study cohorts in two large randomized controlled clinical trials that assess interventions to reduce risk of major cardiovascular disease events in adults with type 2 diabetes in order to explore the feasibility of cross-trial comparisons METHODS: The Action for Health in Diabetes (Look AHEAD) and The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials enrolled 5145 and 10,251 adults with type 2 diabetes, respectively. Look AHEAD assesses the efficacy of an intensive lifestyle intervention designed to produce weight loss; ACCORD tests pharmacological therapies for control of glycemia, hyperlipidemia, and hypertension. Incidence of major cardiovascular disease events is the primary outcome for both trials. A sample was constructed to include participants from each trial who appeared to meet eligibility criteria and be appropriate candidates for the other trial's interventions. Demographic characteristics, health status, and outcomes of members and nonmembers of this constructed sample were compared. RESULTS: Nearly 80% of Look AHEAD participants were projected to be ineligible for ACCORD; ineligibility was primarily due to better glycemic control or no early history of cardiovascular disease. Approximately 30% of ACCORD participants were projected to be ineligible for Look AHEAD, often for reasons linked to poorer health. The characteristics of participants projected to be jointly eligible for both trials continued to reflect differences between trials according to factors likely linked to retention, adherence, and study outcomes. LIMITATIONS: Accurate ascertainment of cross-trial eligibility was hampered by differences between protocols. CONCLUSIONS: Despite several similarities, the Look AHEAD and ACCORD cohorts represent distinct populations. Even within the subsets of participants who appear to be eligible and appropriate candidates for trials of both modes of intervention, differences remained. Direct comparisons of results from separate trials of lifestyle and pharmacologic interventions are compromised by marked differences in enrolled cohorts.
Authors: A Avenell; T J Brown; M A McGee; M K Campbell; A M Grant; J Broom; R T Jung; W C S Smith Journal: J Hum Nutr Diet Date: 2004-08 Impact factor: 3.089
Authors: Thomas A Wadden; Delia S West; Rebecca H Neiberg; Rena R Wing; Donna H Ryan; Karen C Johnson; John P Foreyt; James O Hill; Dace L Trence; Mara Z Vitolins Journal: Obesity (Silver Spring) Date: 2009-01-29 Impact factor: 5.002
Authors: Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski Journal: Control Clin Trials Date: 2003-10
Authors: Mark A Espeland; Jeffery Probstfield; Donald Hire; J Bruce Redmon; Gregory W Evans; Mace Coday; Cora E Lewis; Karen C Johnson; Sharon Wilmoth; Judy Bahnson; Michael F Dulin; Jennifer B Green; William C Knowler; Abbas Kitabchi; Anne L Murillo; Kwame Osei; Shakaib U Rehman; William C Cushman Journal: Am J Hypertens Date: 2015-02-09 Impact factor: 2.689
Authors: Nessa Banville; Janette K Burgess; Jade Jaffar; Gavin Tjin; Luca Richeldi; Stefania Cerri; Elisa Persiani; Judith L Black; Brian G Oliver Journal: PLoS One Date: 2014-08-18 Impact factor: 3.240
Authors: Michael Aschner; Sandra Ceccatelli; Mardas Daneshian; Ellen Fritsche; Nina Hasiwa; Thomas Hartung; Helena T Hogberg; Marcel Leist; Abby Li; William R Mundi; Stephanie Padilla; Aldert H Piersma; Anna Bal-Price; Andrea Seiler; Remco H Westerink; Bastian Zimmer; Pamela J Lein Journal: ALTEX Date: 2016-07-25 Impact factor: 6.043